Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies | Zendy

Patricia LoRusso | Zendy; Alex A. Adjei | Zendy; Mary Varterasian | Zendy; Shirish M. Gadgeel | Zendy; Joel M. Reid | Zendy; David Mitchell | Zendy; Lorelei J. Hanson | Zendy; Pamela DeLuca | Zendy; Laura M. Bruzek | Zendy; Jill Piens | Zendy; Peggy Asbury | Zendy; Keri Van Becelaere | Zendy; Román Herrera | Zendy; Judith S. SeboltLeopold | Zendy; Mark B. Meyer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies

Author(s) -

Patricia LoRusso,

Alex A. Adjei,

Mary Varterasian,

Shirish M. Gadgeel,

Joel M. Reid,

David Mitchell,

Lorelei J. Hanson,

Pamela DeLuca,

Laura M. Bruzek,

Jill Piens,

Peggy Asbury,

Keri Van Becelaere,

Román Herrera,

Judith S. SeboltLeopold,

Mark B. Meyer

Publication year - 2005

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2005.14.415

Subject(s) - medicine , pharmacokinetics , pharmacodynamics , nausea , rash , vomiting , adverse effect , pharmacology , dosing , gastroenterology , cmax , response evaluation criteria in solid tumors , toxicity , maculopapular rash , kinase , phases of clinical research , microbiology and biotechnology , biology

This phase I study was undertaken to define the toxicity, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD), and clinical activity of CI-1040, a small-molecule inhibitor of the dual-specificity kinases MEK(mitogen-activated protein kinase kinase) -1 and MEK2 , in patients with advanced malignancy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research